MLMaciej Lazarek

Maciej Lazarek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maciej Lazarek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HOW TO COMMUNICATE EFFECTIVELY WITH BARIATRIC PATIENTS IN THE TIMES OF GLOBESITY?

    by Zuzanna Kordyś-Wyrobek, Maciej Lazarek, Anna Bych

    Obesity is a condition affecting an increasing number of people worldwide, to the point where it has reached pandemic proportions - "globesity". It significantly increases the risk of other co-morbidities, including cardiovascular disease, dyslipidaemia and type 2 diabetes. Obesity is a serious problem, not only in terms of health but also socio-economically. It is currently believed that bariatric surgery is the most effective method of treating morbid obesity and reducing the risk of associated conditions. Some healthcare professionals harbour negative preconceptions about people with obesity, which is why it is important to train interdisciplinary medical staff in how to collaborate with bariatric patients. In bariatric surgery, this is particularly crucial as it helps to ensure the expected outcomes of the operation are achieved and leads to a significant reduction in the risk of complications.

  • Open Access

    SELECTED CONTEMPORARY THERAPEUTIC STRATEGIES FOR AGE-RELATED MACULAR DEGENERATION: EFFICACY, SAFETY, AND FUTURE DIRECTIONS

    by Zuzanna Kordyś-Wyrobek, Marcelina Skajewska, Maciej Lazarek, Magdalena Iwaszko, Alicja Kamińska, Anna Bych, Emilia Stachula-Mielczarek, Krzysztof Reazka

    Age-related macular degeneration (AMD) is one of the leading causes of irreversible central vision impairment in older adults. The introduction of intravitreal vascular endothelial growth factor (VEGF) inhibitors has fundamentally changed the prognosis of neovascular AMD (nAMD). Contemporary research focuses both on maintaining functional efficacy while reducing treatment burden and on developing effective therapies for geographic atrophy (GA). The aim of this review is to critically evaluate selected contemporary therapeutic strategies used or investigated in AMD, with particular emphasis on efficacy, safety, durability of treatment effect, and the quality of available evidence. The evidence evaluated primarily comprised randomized controlled trials, systematic reviews, and meta-analyses, supplemented by early-phase clinical trials for experimental technologies and post-marketing data when relevant safety signals were identified. The most mature body of evidence demonstrating preservation or improvement of visual function in nAMD concerns anti-VEGF therapy. The PULSAR and TENAYA/LUCERNE trials demonstrated that aflibercept 8 mg and faricimab, respectively, can be administered at extended treatment intervals while maintaining non-inferior functional efficacy compared with active comparators [8–11]. The ranibizumab Port Delivery System (PDS) represents an alternative strategy for reducing the frequency of intravitreal injections but requires surgical implantation [17,18]. In GA, the complement inhibitors pegcetacoplan and avacincaptad pegol have demonstrated modest reductions in the rate of anatomical disease progression [32–34]. These effects should not be interpreted as retinal regeneration or as necessarily translating into improved visual function. For pegcetacoplan, post-marketing safety signals are also clinically relevant [41]. The European Medicines Agency (EMA) did not grant marketing authorization for Syfovre in the European Union, concluding that the demonstrated reduction in GA lesion growth did not translate into a sufficiently meaningful clinical benefit for patients to establish a positive benefit-risk balance [42]. Photobiomodulation demonstrated statistically significant functional outcomes in the LIGHTSITE III program; however, its evidence base remains substantially smaller than that supporting anti-VEGF therapy [35,36]. Gene therapies represent a promising investigational approach, but current evidence is derived predominantly from early-phase studies and is insufficient to establish these treatments as equivalent or superior alternatives to standard anti-VEGF therapy [37,38].

  • Open Access

    THE IMPACT OF HYDRATION ON SLEEP QUALITY AND DURATION: A LITERATURE REVIEW

    by Marcelina Skajewska, Magdalena Iwaszko, Oliwia DziewięCka, Szymon Bojanowski, Aleksandra Wojtera, Krzysztof Reszka, Emilia Stachula-Mielczarek, Zuzanna Kordyś-Wyrobek, Alicja Kamińska, Maciej Lazarek

    Introduction: Adequate hydration is essential for maintaining the body's water balance and overall homeostasis. The relationship between hydration status, fluid intake, and sleep duration and quality remains relatively poorly understood and under-researched. Both insufficient hydration and excessive fluid intake immediately before bedtime may affect the quality of nighttime rest. Objective: The aim of this paper was to summarize current evidence on the relationship between hydration status, the timing of fluid intake, and selected sleep parameters in adults. Materials and methods: A narrative review of the literature available in PubMed was conducted. Publications concerning hydration, dehydration, water and other fluid intake, sleep quality and duration, sleep efficiency, and nocturia were analyzed. Particular attention was given to recent observational and interventional studies, systematic reviews, and meta-analyses published in English. Results: Observational studies provide evidence of associations between hydration status and sleep duration, subjective sleep quality, sleep-onset latency, and sleep efficiency. Findings from experimental studies are less consistent. In some studies, mild dehydration did not significantly affect objective sleep parameters, whereas in others it was associated with greater difficulty falling asleep. Fluid intake before bedtime may increase the risk of nocturia, awakenings, and sleep fragmentation. These relationships were influenced by factors such as age, physical activity, ambient temperature, caffeine, alcohol, chronic diseases, and medications. Conclusions: Hydration status and the timing of fluid intake may affect sleep, but the available evidence does not permit a clear causal relationship to be established. Distributing fluid intake evenly throughout the day and avoiding large volumes immediately before bedtime may have a beneficial effect.

  • Open Access

    DEEP NECK INFECTIONS IN THE GERIATRIC POPULATION - LITERATURE REVIEW

    by Anna Bych, Zuzanna Kordyś-Wyrobek, Maciej Lazarek, Alicja Kamińska, Emilia Stachula-Mielczarek, Krzysztof Reszka

    Introduction and purpose: The aim of the study was to present and briefly discuss the causes of infections of deep neck tissues in geriatric patients. The issue of such factors as multiple diseases, surgical and dental procedures or pharmacotherapy in the geriatric population, which have a significant impact on the course of infection, was discussed. Material and Methods: PubMed, ClinicalKey, and ClinicalTrials.gov were searched for material discussing the course of deep neck tissue infections in the senior population. The works and research from the years 2014-2026 were used, searching for terms such as "deep neck infection", "deep neck infection elderly", "deep neck infection geriatrics", "DNI elderly", "DNI geriatrics", "deep neck infection" age ". The aim was to show the course of DNI in the geriatric population and what mechanisms influence the course of the infections in this age group. Results: Despite the fact that infections of deep neck tissues occur in all age groups, the geriatric population is particularly vulnerable to their aggressive course due to the presence of numerous risk factors, such as taking immunosuppressive drugs, lowered immunity or the presence of comorbidities. Conclusions: There are problems with the diagnosis and treatment of DNI, especially in the elderly population, where the course of these infections may be different than in other age groups. Improper management may lead to health and life-threatening complications. The role of oral health prophylaxis is also very important, and it often does not reach geriatric patients sufficiently.

  • Open Access

    LITERATURE REVIEW: POLYPHARMACOTHERAPY AND ITS NEUROLOGICAL EFFECTS IN THE ELDERLY IN POLAND AND EUROPE

    by Martyna Maria Knopek, Paulina Prudzic, Maciej Lazarek, Kamila Prusinowska Prusinowska, Aleksasndra Sipowicz-Woźniak, Aleksandra H. Piotrowska, Zuzanna Kordyś-Wyrobek, Ewelina Flegiel

    In recent years both in Poland and Europe there have been observed progressive demographic changes and aging of the population. Polypharmacy can be defined as the simultaneous and regular use of at least five different drugs and is particularly often used in elderly patients due to the multimorbidity. According to some sources, elderly people take between two and nine different medications daily, of which even about 60% are inappropriate. The aim of this paper is to summarize information on polypharmacy in seniors in order to plan it as best as possible and at the same time to avoid potential adverse effects, with particular emphasis on the nervous system. One of the most significant for polypharmacy is the age structure of the society. Poland is one of the European countries where the fastest growth of this ratio is observed. Huge problem seems to be the system of educating doctors, which is not adjusted to the changing demographics of the society. Furthermore, one of the factors contributing to polypharmacy is the excessive consumption of dietary supplements by Poles, especially geriatric patients - almost half of Poles consume them regularly. Polypharmacy can be defined as the simultaneous use of at least five different drugs. It is particularly often used in elderly patients due to the multimorbidity and lack of healthcare access. The advantage of polypharmacotherapy is faster achievement of target values, which may improve the patient-doctor relationship, while the disadvantage is the increased risk of side effects. Polypharmacy is a significant problem in the European elderly, to avoid its negative effects, drugs with high bioavailability, short half-lives and a broad therapeutic spectrum are the best choice.